| CAS NO: | 444723-13-1 |
| 包装: | 5mg |
| 市场价: | 1440元 |
| Cas No. | 444723-13-1 |
| Canonical SMILES | CCN(CC)C(C(C=C1)=CC=C1NC2=NC(OCC3CCCCC3)=C4C(N=CN4)=N2)=O |
| 分子式 | C23H30N6O2 |
| 分子量 | 422.52 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs[1]. NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively[2]. Anti-cancer activity[1][2]. cdk2-cyclin A|0.41 μM (IC50)|CDK1-Cyclin B|6.6 μM (IC50)|CDK4-Cyclin D|5.5 μM (IC50)|cdk5-p25|15 μM (IC50)|cdk7-cyclin H|3.9 μM (IC50)|Aurora A|67 nM (IC50)|Aurora B|35 nM (IC50) NU6140 is less active on CDK1-cyclin B, CDK4-cyclin D, CDK5-p25 and CDK7-cyclin H, with IC50s of 0.41, 6.6, 5.5, 15 and 3.9 μM, respectively[1].NU6140 increases catalytic activity of capase-9 and capase-3, causes increase in the sub-G1 apoptotic cell population[1]. [1]. Pennati M, et al. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. |
m.cnreagent.com